MedPath

Comparison of two different Estrogen doses in prevention of synechia after hysteroscopic treatment of Asherman syndrom patients

Phase 2
Recruiting
Conditions
Asherman syndrome.
Intrauterine synechiae
Registration Number
IRCT20141230020486N3
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
60
Inclusion Criteria

all symptomatic patients (infertility or cyclic pelvic pain) referring to gynecology clinic of Imam Reza Hospital who are diagnosed with moderate to severe Asherman syndrome.

Exclusion Criteria

Another pathology in pelvic exam
History of Uterine myoma or gynecology cancer
hormone consumption during past month
History of genital tuberculosis
contraindication for hormone therapy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of people who face recurrence of synechia after treatment of Asherman syndrom. Timepoint: 2 months after using of estrogen. Method of measurement: After treatment period and and bleeding are over, all patients will again go through hysteroscopy and uterine cavity condition will be investigated.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath